Articles On Dimerix (ASX:DXB)

This week’s Bulls N’ Bears Runner of the Week is … Sparc Technologies. The company is developing new-age hydrogen technology using sunlight, while Argent Biopharma, Australian Mines and Dimerix also ran hard.

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

Opyl enters joint venture with X Firm to market its AI-powered TrialKey platform in Europe, Middle East, Africa and North America Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-20...

The ASX200 has been up one fifth of a percent (0.2%) at 8,273 points in afternoon trade. Canada’s Prime Minister Justin Trudeau has resigned and the country’s main stock index fell on Monday; the Loonie notched a near three-week high. Bo...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Fraser Palamara tells all on Dimerix’s (ASX:DXB) new partner in Japan’s FUSO Pharmaceutical Industries to develop a drug candidate in fig...

Dimerix enters exclusive licence deal with Fuso Pharmaceutical Industries to develop and commercialise DMX-200 in Japan to treat FSGS Fuso responsible for development costs, obtaining regulatory approval, sales and marketing in Japan Deal...

Biopharmaceutical company Dimerix Ltd (ASX:DXB) has partnered with Japanese company FUSO to progress the development and commercialisation of its drug DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease....

Dimerix Ltd (ASX: DXB) shares are catching the eye of investors on Tuesday. In morning trade, the ASX healthcare stock is up 31% to 46.5 cents. Why is this ASX healthcare stock rocketing? Investors have been fighting to get hold of the clin...

The ASX 200 index is expected to open as much as 0.36% higher today, adding 29.9 points in futures, which would mark the local bourse’s fourth green day in a row – a trend it just barely held on to yesterday at close. U.S. markets were c...

The second last day of the year on the Australian stock exchange looks red, with the shortened holiday trading week’s futures down just over 29 points – a 0.35% drop – as the Aussie bourse grinds to a sluggish end to the 2025 season. The...

Highlights Market Performance: The ASX dipped 0.35% in early trading as global market pressures and profit-taking weighed on sentiment. Sector Impacts: Key players in tech and retail, including Microsoft and Amazon, showed declines,...

Highlights - ASX faced a modest dip amid global caution and ex-dividend activity.  - BrainChip Holdings (BRN) soared despite no clear catalyst for its rise.  - Prominent small-cap stocks showcased diverse developments and partnerships....

Morgans sees opportunities among several ASX healthcare stocks in 2025 Broker looking at stocks with near-term catalysts or sold down with good entry opportunities Morgans’ Christmas stocking has mix of up-and-comers alongside mature names...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

Syntara aims for FDA ‘breakthrough’ therapy status for its myelofibrosis drug candidate FAK! More promising results from Amplia’s pancreatic cancer trial Oh, you shouldn’t have! Broker Morgans’ Christmas biotech hamper   Armed with encour...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX dips as energy stocks lead losses Global tensions weigh on markets, gold stocks rise China holds rates steady, Nvidia’s earnings later tonight   The ASX slipped from Tuesday’s high, closing lower by 0.57% on Wednesday.  Global worries...

ASX rises, but MinRes drops over transparency issues Fed boss Powell’s cautious rate cut stance cools market optimism NoviqTech shares surge after securing blockchain funding   The ASX rose by 0.74% on Friday, with 10 out of 11 sectors fi...

Several ASX healthcare companies have upcoming catalysts, which can be a focal point for healthcare investors Dimerix forecasts the second interim analysis of its ACTION 3 global phase III trial of DMX-200 to treat FSGS in around mid-CY25...

Botanix has FDA approval for its treatment for hyperhidrosis, or excessive sweating Sufferers have not had an effective treatment for the socially debilitating disorder Broker E&P Financial Group estimates revenues of close to $100 mil...

Stocks surge and US dollar jumps as Trump leads ASX rises  amid tight US election race Bitcoin hits record as Trump-linked trades soar   Stocks surged, Treasury yields soared, and the US dollar looked set for its biggest gain since March...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX opens November lower, led by financial sector sell-off Macquarie Group fell after profit decline Ironbark Zinc jumps 75% on new leadership   The ASX kicked off November with a thud, sliding about 0.5%. This  follows a tough session o...

ASX set to open lower after Wall Street tech stocks slump Amazon soars on strong holiday sales forecast Roblox and Peloton shares surge while Robinhood drops   The ASX is set to fall when the market resumes on Friday after a very rough da...

PARASOL working group confirms eGFR as an approved surrogate endpoint for FDA approval of treatments for focal segmental glomerulosclerosis The working group also determined that proteinuria alone may also be suitable for FDA full approva...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

  ASX hits all-time high before retreating slightly Gold miners surge as prices near record high Hong Kong falls on weak China data; Yen rises     The ASX briefly hit an all-time high on Monday before paring gains. At the close of the da...

The Pilbara Minerals Ltd (ASX: PLS) share price has soared an incredible 20% over the last week, recovering the ground that it lost during the first 10 days of September, as shown on the chart below. It may not come as a complete surp...

The ASX200 has closed up 1.1% at 8,075 points. The Aussie bourse followed Wall Street’s tech sector higher, despite US investors reducing expectations of an up-sized Fed rate cute next week. Back home, all sectors gained ground and the I...

The S&P/ASX 200 Index (ASX: XJO) enjoyed a convincing return to form this Thursday, rising enthusiastically after several days of stagnation. The ASX 200 clos...

  ASX climbs with tech, energy, and uranium stocks driving gains Uranium stocks surge as Putin hints at possible export limits Lithium miners rise on growing demand, while WiseTech hits a new record high   The ASX took a leap on Thursday...

ASX lithium shares are bouncing on Thursday despite the lithium carbonate price trading at three-year lows and their peers in the materials sector lagging the market today. The S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.75% whi...

ASX uranium shares are storming higher today. During the Thursday lunch hour, the All Ordinaries Index (ASX: XAO) is up a healthy 0.8%. And it's getting plenty of support from the uranium miners. Here's how these leading ASX uranium shares...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. In early afternoon trade, the benchmark index is up a sizeable 0.7% to 8,043.7 points. Four ASX shares that are rising more than most today are listed below. Here's...

AML3D Ltd (ASX: AL3) shares are having a strong session on Thursday. In morning trade, the ASX defence stock is up 23% to 16 cents. Why is this ASX defence stock rocketing? Investors have been fighting to get hold of the 3D manufacturing so...

Dimerix Limited (ASX:DXB) has confirmed it’s begun recruiting adolescent kidney disease patients in Mexico, now that its ‘ACTION3‘ Phase 3 clinical trial location has been selected. Ages range from 12 to 17. HotCopper users were perusing...

  ASX falls on Wednesday with banks dragging down market Lithium stocks surge on CATL suspension reports; MinRes hits new high Energy stocks struggle as Brent drops below US$70   The ASX was on the back foot on Wednesday, down by 0.3%  w...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

First patient completes Phase 3 trial and joins Open Label Extension study for its kidney disease drug candidate DMX-200 All patients from its ACTION3 Phase 3 clinical trial are eligible to receive the drug under the OLE Results from study...

Now could be a good time to buy Life360 Inc (ASX: 360) shares. That's the view of analysts at Goldman Sachs, which think the ASX 200 tech stock could deliver market-beating returns over the next 12 months. What is the broker saying about th...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) had a decent session and pushed higher. The benchmark index rose 0.3% to 8,011.9 points. Will the market be able to build on this on Wednesday? Here are five things to watch: ASX 200 expect...

The ASX200 closed up 0.3% at 8,012 points, just below its all time high set a few weeks ago. The local bourse climbed higher as both Commonwealth Bank and Macquarie broke share price records. The Energy sector surged nearly 1%, follow...

Argent Biopharma plans further trials of its cannabinoid-based epilepsy treatment  Argent’s early research work suggests “improved safety profile alongside enhanced efficacy.” The first patient in Dimerix’s pivotal kidney trial enters open...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 8,034.2 points. Four ASX shares that have failed to follow the market higher today...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...